Drug Trial Radar · NCT06554847
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
417
Actual
Start
Sep 23, 2024
Primary completion
Oct 20, 2025
Study completion Aug 18, 2026
Sponsor
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.
Conditions
- Dermatitis, Atopic
- Eczema, Atopic
Interventions
611Drug
subcutaneous injection
PlaceboDrug
subcutaneous injection
Topical corticosteroidDrug
Topical
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving EASI-75 (≥75% reduction from Baseline in EASI score)Time frame: Baseline to Week 16
- Percentage of patients with an IGA score of 0 or 1 and a reduction ≥2-points from Baseline to Week 16.Time frame: Baseline to Week 16
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.